Defining the impact of SARS-COV-2 on delivery of CAR T-cell therapy in Europe: a retrospective survey from the CTIWP of the EBMT

Affiliations

• ¹ Developmental Biology and Cancer, UCL Great Ormond Street Institute of Child Health, London, UK. s.ghorashian@ucl.ac.uk.
• ² Service d'hématologie clinique et de thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, France.
• ³ Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey.
• ⁴ EBMT Statistical Unit, Leiden, The Netherlands.
• ⁵ EBMT Leiden Study Unit, Leiden, The Netherlands.
• ⁶ Hospital Clinic Barcelona, Barcelona, Spain.
• ⁷ Department of Hematology, Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
• ⁸ Hospital de la Princesa, Madrid, Spain.
• ⁹ Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
• ¹⁰ Ospedale San Raffaele s.r.l., Haematology and BMT, Milan, Italy.
• ¹¹ Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer; Centre d'Investigations Cliniques en Biothérapie, Université d'Aix-Marseille, Inserm CBT 1409, Marseille, France.